Gabapentin
Product Images NDC 50090-2590

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50090-2590). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

This is a chart depicting mean pain scores during a study with a 4-week dose titration period followed by a 4-week fixed dose period. The chart compares the mean pain scores of a placebo group with a group taking 3600 mg/day of Gabapentin. The baseline pain score and pain scores at weeks 1 to 8 are shown on the chart.*

FDA Label Image

Figure2 (Figure2)

This is a chart related to a medication study where the dose of Gabapentin was titrated over a 3-week period and then a fixed dose was maintained for 4 weeks. There were 104 participants who either received a placebo or Gabapentin at either 1800mg/day or 2400mg/day. The chart displays the mean pain score over a duration of 7 weeks, including the baseline.*

FDA Label Image

Figure3 (Figure3)

The text describes a chart that shows the proportion of responders in controlled PHN studies at endpoint. The responders mentioned are the patients who have had more than 50% reduction in pain score. The chart consists of percentage values ranging from 0% to 100% in increments of 10. The chart describes two studies- 'Study 1' and 'Study 2'. Under study 1, 'GBP 3600' had 29% responders, 'PBO' had 12% responders. Under study 2, 'GBP 2400' had 34% responders, 'GBP 1800' had 14%, and 'PBO' had 3% responders. The text also mentions some statistical tests carried out which are not entirely discernible.*

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Lbl500902590

FDA Label Image

Scale (Scale)

This text provides a formula for calculating estimated creatinine clearance (CLCr) for patients using their age and serum creatinine level, with a specific adjustment factor for female patients. Not much context is given for how this calculation is to be applied or why it might be useful.*

FDA Label Image

Structuralformula (Structuralformula)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.